Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358068 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04358068 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20 participants.
The verdict
NCT04358068, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
Interventions
- DRUG Hydroxychloroquine (HCQ)
- DRUG Azithromycin (Azithro)
- DRUG Placebo for Hydroxychloroquine
- DRUG Placebo for Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04358068
The ClinicalTrials.gov registry entry for NCT04358068 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Hydroxychloroquine (HCQ) is the first listed.
NCT04358068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04358068 about?
NCT04358068 is a clinical study titled "Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19". The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
What is the current status of trial NCT04358068?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-05-13. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT04358068?
The interventions under investigation include: Hydroxychloroquine (HCQ) (DRUG), Azithromycin (Azithro) (DRUG), Placebo for Hydroxychloroquine (DRUG), Placebo for Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04358068?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.